Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosis
Open Access
- 25 June 2009
- journal article
- research article
- Published by Springer Nature in Journal of Pharmacokinetics and Pharmacodynamics
- Vol. 36 (3) , 239-260
- https://doi.org/10.1007/s10928-009-9120-1
Abstract
Receptor mediated endocytosis (RME) plays a major role in the disposition of therapeutic protein drugs in the body. It is suspected to be a major source of nonlinear pharmacokinetic behavior observed in clinical pharmacokinetic data. So far, mostly empirical or semi-mechanistic approaches have been used to represent RME. A thorough understanding of the impact of the properties of the drug and of the receptor system on the resulting nonlinear disposition is still missing, as is how to best represent RME in pharmacokinetic models. In this article, we present a detailed mechanistic model of RME that explicitly takes into account receptor binding and trafficking inside the cell and that is used to derive reduced models of RME which retain a mechanistic interpretation. We find that RME can be described by an extended Michaelis–Menten model that accounts for both the distribution and the elimination aspect of RME. If the amount of drug in the receptor system is negligible a standard Michaelis–Menten model is capable of describing the elimination by RME. Notably, a receptor system can efficiently eliminate drug from the extracellular space even if the total number of receptors is small. We find that drug elimination by RME can result in substantial nonlinear pharmacokinetics. The extent of nonlinearity is higher for drug/receptor systems with higher receptor availability at the membrane, or faster internalization and degradation of extracellular drug. Our approach is exemplified for the epidermal growth factor receptor system.Keywords
This publication has 41 references indexed in Scilit:
- Population Pharmacokinetics of Cetuximab in Patients With Squamous Cell Carcinoma of the Head and NeckThe Journal of Clinical Pharmacology, 2008
- Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentBritish Journal of Cancer, 2008
- Cell Surface Receptors for Signal Transduction and Ligand Transport: A Design Principles StudyPLoS Computational Biology, 2007
- Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic ProteinsClinical Pharmacokinetics, 2005
- Pharmacokinetic aspects of biotechnology productsJournal of Pharmaceutical Sciences, 2004
- The EGFR as a target for anticancer therapy—focus on cetuximabEuropean Journal Of Cancer, 2001
- Proliferative Response of Fibroblasts Expressing Internalization‐Deficient Epidermal Growth Factor (EGF) Receptors Is Altered via Differential EGF Depletion EffectBiotechnology Progress, 1994
- Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1983
- Evaluation of methods for estimating population pharmacokinetic parameters II. Biexponential model and experimental pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1981
- Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-menten model: Routine clinical pharmacokinetic dataJournal of Pharmacokinetics and Biopharmaceutics, 1980